Scarica l'app Stockscreener
5.39
13.62%
-0.85
Dopo l'orario di chiusura:
5.49
0.10
+1.86%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché RNAZ Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.24
Aprire:
$5.43
Volume 24 ore:
36,985
Relative Volume:
3.67
Capitalizzazione di mercato:
$5.12M
Reddito:
-
Utile/perdita netta:
$-34.66M
Rapporto P/E:
-0.0553
EPS:
-97.5284
Flusso di cassa netto:
$-19.52M
1 W Prestazione:
-12.75%
1M Prestazione:
-36.74%
6M Prestazione:
-41.54%
1 anno Prestazione:
-22.67%
Intervallo 1D:
$5.0101
$5.81
Intervallo di 1 settimana:
$5.0101
$6.55
Portata 52W:
$5.0101
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Nome
Transcode Therapeutics Inc
Settore
Industria
Telefono
857-301-6857
Indirizzo
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
5.39 | 5.93M | 0 | -34.66M | -19.52M | -97.53 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie
TransCode Therapeutics Files 8-K/A Detailing Nasdaq Compliance Plan and Soliciting Material Disclosure - Minichart
Nasdaq warns TransCode (NASDAQ: RNAZ) on equity shortfall and delisting risk - Stock Titan
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice - TipRanks
TransCode Therapeutics (RNAZ) Surges 2% as Biotech Stock Tests Key Resistance at $6.55Head and Shoulders - Newser
TransCode Therapeutics (NASDAQ: RNAZ) warned on Nasdaq equity shortfall - Stock Titan
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
[EFFECT] Transcode Therapeutics, Inc. SEC Filing - Stock Titan
What TransCode Therapeutics RNAZ flagged as biggest challenges ahead Q4 2024 Below ExpectationsQuarterly Earnings - Newser
TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Transcode Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Mesa Air Group, Inc.Common Stock (NQ: MESA - FinancialContent
What you need to know before buying TransCode Therapeutics (RNAZ) (Breakdown Watch) 2026-05-11Fast Rising Picks - newser.com
What TransCode Therapeutics (RNAZ) flagged as biggest challenges ahead | Q4 2024: Below ExpectationsHigh Interest Stocks - newser.com
Trading Systems Reacting to (RNAZ) Volatility - Stock Traders Daily
TransCode Therapeutics (RNAZ) asks shareholders to OK preferred conversions, SEPA funding - Stock Titan
How TransCode Therapeutics (RNAZ) differentiates itself from competitors (Near Highs) 2026-05-08Open Stock Signal Network - newser.com
TransCode Therapeutics 2025 10-K/A: Executive Compensation, Board Members, and Corporate Governance Overview - Minichart
TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) updates 2025 governance, executive pay and ownership - Stock Titan
MSN Money - MSN
TransCode names Anna Moore scientific board chair - Investing.com UK
TransCode Therapeutics Appoints Dr. Anna Moore as Scientific Advisory Board Chair, Signs Research Agreement with Michigan State University - citybuzz -
TransCode names Anna Moore scientific board chair By Investing.com - Investing.com Australia
Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board - marketscreener.com
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University - PR Newswire
RNAZ News | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics signs financing deal worth up to $20 million - MSN
RNAZ (TransCode Therapeutics Inc.) posts far wider than expected Q4 2024 loss, shares notch small gain in today’s trading.Asset Sale - Xã Thanh Hà
TransCode Therapeutics (RNAZ) Stock: Volatility Overview (-4.45%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
YA II affiliates report 101,772 shares in TransCode Therapeutics (RNAZ) under convertible note - Stock Titan
(RNAZ) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TransCode Therapeutics 2025 10-K: Advancing RNA and Immuno-Oncology Cancer Therapeutics with Proprietary TTX Platform - Minichart
TransCode Therapeutics (RNAZ) Stock Dual Listing (Smart Money Flows) 2026-04-15Verified Signals - Xã Thanh Hà
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) expands cancer pipeline with Polynoma and Unleash deals - Stock Titan
TransCode Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Weekly: Is TransCode Therapeutics Inc showing insider buying2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Geopolitics Watch: Can TransCode Therapeutics Inc sustain its profitability - baoquankhu1.vn
Chipmakers Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averaging2026 Macro Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Big Picture: What is TransCode Therapeutics Incs P E ratio telling us2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Insider Sell: Why is TransCode Therapeutics Inc stock going downEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
TransCode Therapeutics Secures New Financing to Extend Runway - The Globe and Mail
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - Bitget
TransCode Therapeutics Secures Up to $20 Million Financing for Metastatic Cancer Trial - citybuzz -
TransCode Therapeutics Secures Up to $20 Million Flexible Financing to Advance Lead Cancer Program and Extend Runway Into 2028 - Minichart
Eightco (NASDAQ: ORBS) Represents the Biggest Public Market Exposure to OpenAI for Retail Investors - Weekly Voice
TransCode Therapeutics Secures $20M Financing - citybiz
Transcode Therapeutics Secures Up To $14 Million Standby Equity Facility and $6 Million Notes With Yorkville - TradingView — Track All Markets
Transcode Therapeutics Inc Azioni (RNAZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):